Metastatic Breast Cancer Clinical Trials in Montvale, New Jersey

9 studies are recruiting for metastatic breast cancer in Montvale, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hor…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center Bergen, Montvale, New Jersey
    Locations
    79 in total
    Run by
    BioNTech SE
  2. A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

    Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  3. A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

    The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
    Locations
    8 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  4. A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

    The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  5. A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

    The purpose of this study is to test different doses of abemaciclib to find the best dose in participants while receiving hormone therapy and radiation therapy.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  6. A Study of Surgery and Radiotherapy in People With Breast Cancer

    The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  7. Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

    This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Bergen, Montvale, New Jersey
    Locations
    12 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  8. A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

    The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
    Locations
    12 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  9. A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

    The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radi…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.